This post uses hypothetical scenarios for illustrative purposes only. It does not describe any actual client, transaction, or representation, and is not legal advice.
A common Florida deal pattern looks like this: a multistate cannabis operator wants into Florida, and the only realistic door is buying one of the state’s licensed medical marijuana treatment centers. The target’s revenue is fine, its dispensaries are busy, and the price reflects none of that — the price is the license. Florida caps the number of MMTC licenses by statute, so the license trades at a premium that would make a liquor-quota-license broker blush. And then the buyer’s deal team, accustomed to change-of-control filings that run in parallel with closing, reads section 381.986 and discovers that the Department of Health sits in the middle of this transaction with a sixty-day runway and an effective veto.
The license is the asset, and the statute decides how it moves
Florida’s medical marijuana regime lives in , and paragraph (8)(e) does two structural things at once. First, it makes every MMTC vertically integrated as a matter of law: a licensed treatment center must cultivate, process, transport, and dispense marijuana for medical use, and it generally cannot contract out the functions directly related to those activities. There is no buying just the cultivation side or just the retail footprint — the license describes a whole seed-to-sale enterprise, and that is what the buyer is acquiring, staffing and all. Second, the statute expressly contemplates that the license can change hands: an MMTC may “transfer ownership to an individual or entity who meets the requirements” of the section, and a publicly traded company that qualifies is not precluded from ownership. So the deal is doable. It just is not doable on the buyer’s schedule.
The mechanics are where deal timelines go to be humbled. To accommodate a change in ownership, the licensed MMTC must notify the department in writing at least sixty days before the anticipated date of the change. The individual or entity applying for licensure because of the change of ownership must submit its own application, and the department must receive it at least sixty days before the ownership change occurs. The department then has thirty days to examine the application and notify the applicant of apparent errors or omissions and request additional information. Read those provisions together and the practical consequence is that signing and closing cannot be simultaneous in a Florida MMTC deal. There is a mandatory regulatory season between them — sixty days at an absolute statutory minimum, and longer in practice once completeness review and follow-up requests do their work.
The buyer inherits the seller’s regulatory skin
The Department of Health’s implementing rule for ownership transfers adds the part that should reorder the buyer’s diligence priorities. A transfer processed without department approval is not a foot fault: the department takes the position that an unauthorized transfer results in suspension of the MMTC’s ability to operate until a proper transfer request is submitted and approved. That converts a closing-mechanics question into an existential one — an impatient buyer who closes first and files second has purchased a suspended business.
Just as important, upon an approved transfer the new owner assumes responsibility and liability for the prior owner’s violations of statute and rule and steps into the prior owner’s regulatory obligations. And the transferee must operate the treatment center in accordance with the representations made in the original license application — plus any approved variances — on file with the department. Sit with that for a moment, because it is unusual. In most regulated-industry deals, the buyer diligences the target’s permits and its compliance history. Here the buyer must also diligence a document that may be a decade old: the application on which the license was originally issued. Those application representations are not marketing history; they are the operating charter the buyer will be held to on day one. The statute does allow the department to grant a variance from the procedures and standards represented in the initial application, but only where the department can reasonably determine the change is not a lower standard than what was represented — and some requirements cannot be varied at all. A buyer whose post-closing operating plan differs from the seller’s original application needs to know that before pricing the deal, not after.
Structure follows the statute, not the tax model
The usual Florida framework for choosing between an asset deal and an equity deal gets inverted here. An asset deal in the classic sense — buyer’s newco purchases the dispensaries, inventory, and goodwill, and the license is assigned over like a contract — is not how this statute works. The license is not an assignable asset sitting on a schedule; moving it to a new person or entity is precisely the “transfer of ownership” that requires the new owner to apply and be approved. Equity deals keep the licensed entity intact, but they do not escape the department either: the regulator distinguishes between a transfer of the license to a new entity and changes in the ownership of the existing licensee, and both routes run through Tallahassee, on forms and timelines the department prescribes. The structuring conversation is therefore less “asset versus stock” and more “which department process applies, and how do we build the purchase agreement around it.”
That means the purchase agreement earns its fee in the covenants. Department approval belongs as an express condition to closing, with a realistic outside date — sixty days is the statutory floor, not an estimate. The interim operating covenants matter more than usual because the seller is running a business the buyer will answer for: compliance failures between signing and closing become the buyer’s inherited record at closing. Sellers should negotiate for meaningful control over the regulatory filings and communications, since the seller’s license is the thing at risk if the process is botched. And both sides should think hard about what happens if the department requests information the buyer cannot or will not provide — the financial and background disclosures required of an applicant reach into the buyer’s ownership structure, and a private equity buyer with layered funds should map who must be disclosed before signing, not during completeness review.
The cannabis overlay changes the ordinary deal toolkit
Everything above sits on top of the awkward fact that marijuana remains a federal controlled substance, and the standard M&A toolkit shrinks accordingly. Representation and warranty insurance is generally unavailable or heavily excluded for plant-touching businesses, so indemnity structures revert to old-fashioned escrows and holdbacks — which themselves require a bank willing to hold cannabis-adjacent funds. Section 280E of the Internal Revenue Code distorts the target’s after-tax economics and therefore the quality-of-earnings work. Institutional lenders are scarce, so seller financing appears frequently, and a seller taking back paper should think carefully about remedies: a security interest in the license itself is not a realistic backstop when the license cannot move without department approval. None of this makes the deals unworkable — Florida MMTC licenses have traded, repeatedly and at scale — but it does mean the diligence checklist needs a cannabis chapter, and the closing checklist needs the Department of Health at the top rather than the bottom.
The takeaway
A Florida MMTC acquisition is a license deal wearing an operating company’s clothes. Section 381.986(8)(e) permits the transfer but dictates its rhythm: sixty days of advance notice, an initial-licensure application from the buyer, a completeness review, and department approval before the change of ownership occurs — with suspension as the price of jumping the gun, and with the buyer assuming the seller’s regulatory liabilities and the seller’s original application representations at the moment of closing. The deals that go well treat the department as the third party at the table from the first draft of the LOI: condition, covenant, outside date, and a diligence file that starts with the oldest document in the data room. A well-run M&A process can absorb a sixty-day regulatory season; it cannot absorb discovering one at closing.
If you are buying or selling a Florida medical marijuana treatment center or structuring a cannabis acquisition, feel free to reach out to my firm manager, Magda, at Magda@montague.law, or fill out our contact form. Mention you read this post.
